Thymosin Alpha-1 (Immune Support)

Rost 1999: nine Caucasian volunteers,900 microgram/m² SC, three-way formulation crossover, single and 5 day administration; Tmax 1–2 h, half-life<3 h. Use 2 h/1.5 h as explicitly inferred representative timing, not a reported fitted parameter pair.

One 1 mg input peaks at 1 relative unit after a single dose. Other amounts scale proportionally; overlapping doses add when accumulation is on. Different compounds use separate relative scales.

Timing half-life used

2 hours

Absorption half-life assumed

0.6075545 hours

Reference amount for the relative scale

1 mg

• The faster rate is inferred to match the 1.5 h source-scoped peak time; absorption half-life 0.6075545274580504 h is a mathematical shape parameter, not separately measured.
• A single 1-unit input has a peak of 1 relative unit; scaling and repeated-dose addition are mathematical assumptions. This normalization is independent of the example dose.
• Zadaxin/Timosina/Talpha 1-HLR show different exposure.
• The 63 ng/mL at 1.6 mg value is present in a 2024 review but primary product/cohort linkage was not established in this pass.
• Apparent volumes/clearance already include F.

• Pharmacokinetics of thymosin alpha1 after subcutaneous injection of three different formulations in healthy volunteers.

  Rost 1999: nine Caucasian volunteers,900 microgram/m² SC, three-way formulation crossover, single and 5 day administration; Tmax 1–2 h, half-life<3 h. Use 2 h/1.5 h as explicitly inferred representative timing, not a reported fitted parameter pair.

• FDA2024 thymosin-alpha1 scientific review

  Clinical and formulation evidence reviewed; original Rost citation located. Rat PK and salt/free-base distinctions must not calibrate this human entry.

thymosin-alpha-1-relative-timing-2026-10 · version 1